Vertex Pharma (VRTX) Tops Q1 EPS by 68c; reiterates guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $508.34 -1.55%
Revenue Growth %: +10.7%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +10.7%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $4.76, $0.68 better than the analyst estimate of $4.08. Revenue for the quarter came in at $2.69 billion versus the consensus estimate of $2.58 billion.
GUIDANCE:
Vertex Pharma sees FY2024 revenue of $10.55-10.75 billion, versus the consensus of $10.718 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
